Hormone-dependent prostate cancer
Not recruitingStudy comparing darolutamide versus hormone therapy (goserelin, leuprorelin, triptorelin, degarelix) in men with untreated hormone-sensitive prostate cancer
Study comparing darolutamide versus hormone therapy (goserelin, leuprorelin, triptorelin, degarelix) in men with untreated hormone-sensitive prostate cancer
- Disease:Hormone-dependent prostate cancer
- Substances:DarolutamideGoserelin Acetate+3
Spain- Participants:18–64 years · 65+ years
- Substances:Darolutamide
- Sponsor:European Organisation For Research And Treatment Of Cancer











